Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est

Benzinga Newsdesk www.benzinga.com Positive 94.4%

Neg 0% Neu 0% Pos 94.4%

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.